Both the PROFILE and ALEX studies confirmed that the above-targeted agents could significantly improve the OS and PFS of patients with non-small cell lung cancer with ALK gene mutation compared with standard chemotherapy [58, 59]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.